BeiGene (ONC) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending approval of Tevimbra in combination with etoposide and platinum chemotherapy, as a first-line treatment for adult patients with extensive-stage small cell lung cancer.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeiGene price target raised to $259 from $207 at Bernstein
- BeiGene’s Strong Market Position and Growth Potential: A Buy Rating by Reni Benjamin
- BeiGene announces FDA approval of Tevimbra/chemotherapy combination
- BeiGene upgraded to Buy from Neutral at BofA
- BeiGene’s Strong Market Position and Growth Potential Driven by Zanubrutinib Sales and Promising Financial Outlook